Revelation Share Price

Revelation Share Price

NASDAQ: REVB | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Revelation Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
$0.45 - $4.39
Volume
N/A
Average Traded
N/A

Revelation Share Price Chart

Line chart of the Revelation price trend over the selected period. The price rose overall, ranging from 3.96 to 4.01, ending at 3.96.
$0.00$0.00
L
Show Current Price
H

Revelation Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-31.35
Revenue (TTM)
$0.00
Return On Equity (TTM)
-246.63%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-32.27%

Revelation Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$2.51-$8.69-$3.32-$3.32
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-246.22%61.80%0.00%

Revelation Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$10.83-$0.12-$15.04-$14.87
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A98.89%-12433.33%1.13%

Revelation Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.770.060.070.09
Current Assets10.816.5712.155.41
Total Assets11.586.6212.215.5
Non Current Liabilities0.720.00.00.0
Current Liabilities2.01.915.564.45
Total Liabilities2.721.915.564.45
Shareholders' Equity8.864.716.651.05

Revelation Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-8.27-18.32-7.29-11.22
Investing0.0-0.020.00.0
Financing12.4712.8514.0315.2

Corporate Actions

Split
Ex-date: 20 Oct 2026

Split
Ex-date: 28 Jan 2026

Split
Ex-date: 07 Jul 2025

Split
Ex-date: 28 Jan 2025

Split
Ex-date: 25 Jan 2024

Split
Ex-date: 01 Feb 2023

About Revelation

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Revelation Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.90
$3.96
-1.00%
Oct 2026
$0.77
$4.00
+387.80%
Sep 2026
$0.98
$0.82
-20.39%
Aug 2026
$1.01
$1.03
+8.42%
Jul 2026
$1.04
$0.95
-7.77%
Jun 2026
$1.06
$1.03
-6.36%
May 2026
$1.05
$1.10
-4.35%
Apr 2026
$1.21
$1.15
-6.50%
Mar 2026
$1.30
$1.23
-6.82%
Feb 2026
$1.89
$1.32
-34.16%
Jan 2026
$0.81
$2.00
+152.20%
Dec 2025
$0.98
$0.80
-17.70%

Revelation Share Price FAQs